Hydrocodone bitartrate is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5); also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5); a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine; and may be represented by the following structural formula:
Image may be NSFW. Clik here to view. ![]() |
Hydrocodone Bitartrate
C18H21N03•C4H606•2.5 H20
Molecular weight = 494.5
Purdue’s hydrocodone bitartrate tablets granted priority review designation
Purdue Pharma has been granted priority review designation by the US Food and Drug Administration (FDA) for its hydrocodone bitartrate extended-release tablets for treatment of chronic pain.
The once-daily, single-entity pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for misuse or abuse by various routes of administration.http://www.pharmaceutical-technology.com/news/newspurdues-hydrocodone-bitartrate-tablets-granted-priority-review-designation-4313765?WT.mc_id=DN_News
Filed under: Priority review Tagged: hydrocodone bitartrate, priority review designation, Purdue Image may be NSFW.
Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.
